Direct to Consumer
To aid in the fight against the COVID-19 pandemic, the Direct-to-Consumer (DTC) working group came together to identify rapid diagnostics and mobile health solutions with potential to be deployed within our healthcare system and beyond. An overview of these efforts, which were accomplished through the collective altruism from the researchers, clinicians and staff from across the MGB healthcare system along with collaborators from around the country and the globe, is highlighted below. The full details of this work can be found in this medRxiv manuscript. Results from our clinical evaluations of these products will be posted as they become are available.
COVID-19 Rapid Tests
In response to the urgent public health need for accurate, effective, low-cost, and scalable COVID-19 testing technology, the Direct-To-Consumer (DTC) working group within the Mass General Brigham (MGB) Center for COVID-19 Innovation was tasked with identifying viable diagnostic solutions with potential for use as a DTC product. To identify potential products, we performed a deep horizon scan for antigen and serology based diagnostics and down selected to the most promising. Product evaluations are based entirely on company provided data. Those that passed our first scoring algorithm based on Specificity and Sensitivity data were then further evaluated by our second scoring algorithm based on additional technical specifications in combination with data about the company and distribution capacity. The results of these efforts are displayed in the table below. All blank fields represent information we were unable to obtain. The performance metrics for some of the high scoring products are currently being validated in-house through the Diagnostics Accelerator. Once complete, this data will be made available.
Antibody Tests: Horizon Scanning Results
Horizon Scan: Workflow
Horizon Scan: Methodology
Table 1: Scoring Metrics
Contact Tracing Assessment
The information contained on this website is provided by the MGB Center for COVID Innovation (MGB-CCI) and is for general information purposes only and is not intended to be used as a reference for funding or grant proposals. In no case does the inclusion or exclusion of products or information contained on this website represent an endorsement nor should it be interpreted as judgement on validity or legitimacy of tests. While we attempt to keep the information current and correct, MGB-CCI cannot and does not guarantee the accuracy, reliability, suitability or completeness of the information and products contained on the website for any purpose. Any reliance placed on such information is therefore solely at your own risk.
In no case will MGB-CCI be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of or in connection with the use of this website.
Links contained within this website direct to other websites that are not maintained by MGB-CCI. We have no control over the nature, content and availability of those sites and the inclusion of these links does not necessarily imply a recommendation or endorsement of the views expressed within them.